Publications

Selected Publications

 

Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse. Araujo JA, Meng L, Tward AD, Hancock WW, Zhai Y, Lee A, Ishikawa K, Iyer S, Buelow R, Busuttil RW, Shih DM, Lusis AJ, Kupiec-Weglinski JW. J Immunol. 2003 Aug 1;171(3):1572-80.

Trypanosoma congolense: paraoxonase 1 prolongs survival of infected mice. Bhasin KK, Yu JM, Tward A, Shih D, Campbell DA, Lusis AJ. Exp Parasitol. 2006 Nov;114(3):240-5. Epub 2006 May 8.

Comprehensive genomic characterization of head and neck squamous cell carcinomas. Cancer Genome Atlas Network. Nature. 2015 Jan 29;517(7536):576-82. doi:10.1038/nature14129.

Expression of human paraoxonase (PON1) during development. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE. Pharmacogenetics. 2003 Jun;13(6):357-64.

Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. Cole TB, Walter BJ, Shih DM, Tward AD, Lusis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. Pharmacogenet Genomics. 2005 Aug;15(8):589-98.

Paraoxonase 1 (PON1) status and risk of insecticide exposure. Furlong CE, Cole TB, Walter BJ, Shih DM, Tward A, Lusis AJ, Timchalk C, Richter RJ, Costa LG. J Biochem Mol Toxicol. 2005;19(3):182-3.

Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Furlong CE, Cole TB, Jarvik GP, Pettan-Brewer C, Geiss GK, Richter RJ, Shih DM, Tward AD, Lusis AJ, Costa LG. Neurotoxicology. 2005 Aug;26(4):651-9.

Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Gatti RA, Tward A, Concannon P. Mol Genet Metab. 1999 Dec;68(4):419-23.

Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Nat Med. 2007 Jul;13(7):820-7. Epub 2007 Jun 24.

Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer. Lee SA, Ho C, Roy R, Kosinski C, Patil MA, Tward AD, Fridlyand J, Chen X. Hepatology. 2008 Apr;47(4):1200-10. doi: 10.1002/hep.22169.

Reciprocal interaction of Wnt and RXR-α pathways in hepatocyte development and hepatocellular carcinoma. Li J, Chanrion M, Sawey E, Wang T, Chow E, Tward A, Su Y, Xue W, Lucito R, Zender L, Lowe SW, Bishop JM, Powers S. PLoS One. 2015 Mar 4;10(3):e0118480. doi: 10.1371/journal.pone.0118480. eCollection 2015.

Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusis AJ, Furlong CE. Pharmacogenetics. 2000 Dec;10(9):767-79.

High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. Cancer. 2013 Aug 15;119(16):3034-42. doi: 10.1002/cncr.28150. Epub 2013 May 20.

Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. Mroz EA, Tward AD, Hammon RJ, Ren Y, Rocco JW. PLoS Med. 2015 Feb 10;12(2):e1001786. doi:10.1371/journal.pmed.1001786. eCollection 2015 Feb.

Characterization of HPV and host genome interactions in primary head and neck cancers. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R; Cancer Genome Atlas Network. Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15544-9. doi: 10.1073/pnas.1416074111. Epub 2014 Oct 13.

Auditory brainstem implantation in a 16-month-old boy with cochlear hypoplasia. Puram SV, Tward AD, Jung DH, Dilger AE, Herrmann BS, Duhaime AC, Barker FG 2nd, Lee DJ. Otol Neurotol. 2015 Apr;36(4):618-24. doi: 10.1097/MAO.0000000000000676.

Hepatocellular carcinoma in Txnip-deficient mice. Sheth SS, Bodnar JS, Ghazalpour A, Thipphavong CK, Tsutsumi S, Tward AD, Demant P, Kodama T, Aburatani H, Lusis AJ. Oncogene. 2006 Jun 15;25(25):3528-36. Epub 2006 Apr 10.

Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, Gladstone H, Chang HY, Morganroth GS, Oro AE, Brown PO. Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14842-7. Epub 2006 Sep 26.

The mutational landscape of head and neck squamous cell carcinoma. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science. 1208130. Epub 2011 Jul 28.

Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM. Circulation. 2002 Jul 23;106(4):484-90.

Distinct pathways of genomic progression to benign and malignant tumors of the liver. Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, Kay MA, Wang R, Bishop JM. Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14771-6. Epub 2007 Sep 4.

Genomic progression in mouse models for liver tumors. Tward AD, Jones KD, Yant S, Kay MA, Wang R, Bishop JM. Cold Spring Harb Symp Quant Biol. 2005;70:217-24.

MSJAMA. From grave robbing to gifting: cadaver supply in the United States. Tward AD, Patterson HA. JAMA. 2002 Mar 6;287(9):1183.